Background {#Sec1}
==========

Thrombolysis treatment with intravenous recombinant human tissue plasminogen (tPA) is currently the only widely approved medical treatment for acute ischemic stroke. In selected patients, it has been found to improve functional recovery with an acceptable risk (The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group [@CR2]; Hacke et al. [@CR10]; Wardlaw et al. [@CR27]). According to the etiology, ischemic stroke can be classified into several subtypes which may be related to a different prognosis (Ois et al. [@CR22]), most likely due to differences in the mechanism.

Although tPA has been shown to be effective in previous reports, few studies have evaluated its efficacy and complications between ischemic stroke subtypes after thrombolysis. In the National Institute of Neurological Disorders and Stroke (NINDS) and European Cooperative Acute Stroke Study (ECASS) studies (The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. [@CR2]; Hacke et al. [@CR10]), the use of tPA was not restricted to patients with small vessel disease (SVD), and whether or not thrombolysis is beneficial for these patients is under debate. In addition, the efficacy of tPA has been reported to be related to the size, composition and origin of the thrombus (Molina et al. [@CR19]). In addition, although the fresh blood clots originating mainly from cardioembolism (CE) stroke can be more easily dissolved by thrombolytic agents than old blood clots, patients with CE stroke are generally older with more severe strokes. These factors may mean that there is no difference in outcome between patients with CE and large-artery atherosclerosis (LAA) stroke (Fuentes et al. [@CR8]; Mustanoja et al. [@CR20]). The purpose of this study was to analyze the outcomes and complications between stroke subtypes after intravenous tPA treatment.

Subjects and methods {#Sec2}
====================

We retrospectively analyzed the clinical data of patients with acute ischemic stroke who received intravenous tPA treatment at a Chang Gung Memorial Hospital (there are four branches at Linkou, Kaohsiung, Keelung, and Chiayi) from January 2007 to April 2014. The clinical data of these acute stroke patients were prospectively registered in the Chang Gung Stroke registry databank. We identified 499 patients who received intravenous tPA treatment, 28 of whom with a baseline modified Rankin scale (mRS) score \>1 were excluded. A total of 471 patients were analyzed and classified according to the Trial of Org 10172 in Acute Stroke Treatment (TOAST), including LAA, CE, SVD, undetermined etiology (UnD) and other determined etiology. The outcomes after intravenous thrombolysis included mRS on discharge from the hospital, symptomatic intracranial hemorrhage (sICH), any hemorrhage, and mortality. A good outcome was defined as a mRS score ≤2, and a favorable outcome was defined as a mRS score ≤1. Symptomatic ICH was defined according to the ECASS criteria (Hacke et al. [@CR10]). The study was approved by the Institutional Review Board of Chang Gung Memorial Hospital (ethical license No.: 102-4340B).

Statistical analysis {#Sec3}
--------------------

All statistical analyses were performed using the Statistical Program for Social Sciences (SPSS) statistical software (version 18). Continuous variables were expressed as mean ± standard deviation or median and interquartile range. Variables were compared using the Kruskal--Wallis test, and a Bonferroni-corrected Mann--Whitney U test was used to identify which two-by-two comparisons were significantly different. Rates of different categories among the groups were compared using the Chi square test. A multivariate logistic regression model was used to evaluate the outcomes after adjusting for baseline variables with a *p* value \<0.1 in univariate analysis. All statistical tests were two-tailed, and a *p* value of \<0.05 was considered to be statistically significant.

Results {#Sec4}
=======

Of the 471 patients who received intravenous tPA treatment, 82 (17.6 %) had SVD, 148 (31.8 %) had CE, 117 (25.1 %) had LAA, 119 (25.5 %) had UnD, and 5 (1.1 %) had other determined etiology. The other determined etiology was not analyzed because of the small number of patients. The demographic data of these patients are shown in Table [1](#Tab1){ref-type="table"}. The patients with SVD had the mildest stroke severity (median NIHSS = 7), while those with CE had the worst stroke severity (median NIHSS = 15). The initial NIHSS in the patients with SVD was significantly lower than in those with CE (*p* \< 0.001) and LAA (*p* \< 0.001). The patients with CE were the oldest among all stroke subtypes, and it was significantly different compared to those with LAA (*p* \< 0.001). The patients with LAA were predominantly male, and there were significant differences compared to those with CE (*p* \< 0.001) and SVD (*p* = 0.004). Because atrial fibrillation was used to determine the diagnosis of CE stroke, the ratio was higher in the patients with CE stroke than in those with other stroke subtypes (CE vs. LAA, *p* \< 0.001; CE vs. SVD, *p* \< 0.001; CE vs. UnD, *p* \< 0.001). Congestive heart failure was more prevalent in the patients with CE than in those with other stroke subtypes, whereas hyperlipidemia was less prevalent in the patients with CE than in those with LAA (*p* = 0.001) and SVD (*p* = 0.003). There were no differences between the stroke subtypes in other stroke risk factors, time to the initiation of tPA treatment or initial blood pressure.Table 1The demographic data of patients with IV tPA treatmentSVDCELAAUnD*p*N82148117119Age (mean ± SD)64.5 ± 11.368.3 ± 11.561.5 ± 13.264.9 ± 13.1\<0.001Sex (F/M)34/4874/7426/9139/80\<0.001Atrial fibrillation (%)0 (0 %)136 (91.9 %)2 (1.7 %)43 (36.1 %)\<0.001Diabetes mellitus (%)30 (36.6 %)36 (24.3 %)30 (25.6 %)35 (29.4 %)0.220Hypertension (%)68 (82.9 %)110 (74.3 %)89 (76.1 %)91 (76.5 %)0.516Hyperlipidemia (%)46 (56.1 %)49 (33.1 %)62 (53.0 %)58 (48.7 %)\<0.001Coronary artery disease (%)3 (3.7 %)23 (15.5 %)13 (11.1 %)12 (10.1 %)0.051Congestive heart failure (%)1 (1.2 %)19 (12.8 %)2 (1.7 %)3 (2.5 %)\<0.001Old stroke (%)16 (19.5 %)18 (12.2 %)17 (14.5 %)19 (16.0 %)0.503Smoking (%)27 (32.9 %)34 (23.0 %)40 (34.2 %)39 (32.8 %)0.214Prior antiplatelet treatment (%)13 (15.9 %)47 (31.8 %)13 (11.1 %)26 (21.8 %)\<0.001Prior anticoagulant treatment (%)1 (1.2 %)10 (6.8 %)0 (0 %)3 (2.5 %)0.008Systolic BP (mmHg)156.1 ± 21.7148.4 ± 27.8152.0 ± 25.0148.1 ± 21.80.064Diastolic BP (mmHg)86.6 ± 14.586.3 ± 18.185.6 ± 16.084.0 ± 13.70.814Onset to tPA time (min)135.7 ± 46.2133.5 ± 71.6135.3 ± 42.2132.5 ± 42.00.647NIHSS baseline, median (IQR)7 (6--10)15 (9--20)12 (8--18)11 (7--17)\<0.001NIHSS 2 h, median (IQR)5 (4--8.25)13 (7--18)11 (7--16)9 (5--16)\<0.001NIHSS discharge, median (IQR)3 (1--6.25)7 (2--15)7 (3--13)6 (2--11)\<0.001MRS admission, median (IQR)4 (2--4)4 (4--5)4 (4--5)4 (3--5)\<0.001MRS discharge, median (IQR)1.5 (1--4)4 (1--5)4 (1.5--5)3 (1--5)\<0.001MRS at discharge ≤141 (50.0 %)40 (27.0 %)29 (24.8 %)36 (30.3 %)0.001MRS at discharge ≤249 (59.8 %)43 (29.1 %)38 (32.5 %)45 (37.8 %)\<0.001Symptomatic ICH1 (1.2 %)17 (11.5 %)5 (4.3 %)7 (5.9 %)0.012Any ICH2 (2.4 %)50 (33.8 %)28 (23.9 %)19 (16.0 %)\<0.001Mortality0 (0 %)15 (10.1 %)5 (4.3 %)6 (5.0 %)0.011

There was a significant difference between stroke subtypes in favorable and good outcomes (*p* \< 0.001). The patients with SVD had the highest ratio of good and favorable outcomes compared to the other stroke subtypes (good outcome: SVD--CE *p* \< 0.001, SVD--LAA *p* \< 0.001, SVD--UnD *p* = 0.001; favorable outcome: SVD--CE *p* \< 0.001, SVD--LAA *p* \< 0.001, SVD--UnD *p* = 0.002). The higher ratio of favorable outcome between SVD and LAA was still significantly different after adjusting for confounding factors (Table [2](#Tab2){ref-type="table"}). Furthermore, a lower initial NIHSS was associated with favorable and good outcomes, and younger age was associated with favorable outcome (Table [2](#Tab2){ref-type="table"}).Table 2Multivariate logistic regression model for outcomesFavorable outcomeGood outcomeSymptomatic ICHAny hemorrhageMortalityOdds ratio*p*Odds ratio*p*Odds ratio*p*Odds ratio*p*Odds ratio*p*TOAST0.0370.0800.5030.003 LAA versus SVD0.39 (0.18--0.69)0.0050.46 (0.23--0.83)0.0112.50 (0.27--23.7)0.42311.03 (2.51--48.6)0.002 CE versus SVD0.69 (0.28--1.70)0.4150.73 (0.30--1.78)0.4825.60 (0.54--58.5)0.15012.26 (2.43--61.9)0.003 UnD versus SVD0.53 (0.28--1.03)0.0590.60 (0.31--1.14)0.1183.84 (0.42--35.2)0.2346.07 (1.31--28.1)0.021 CE versus LAA1.76 (0.72--4.29)0.2151.67 (0.70--3.96)0.2482.24 (0.49--10.2)0.2971.11 (0.46--2.72)0.816Initial NIHSS0.92 (0.89--0.96)\<0.0010.91 (0.88--0.95)\<0.0011.08 (1.02--1.14)0.0071.03 (0.995--1.07)0.0911.13 (1.07--1.20)\<0.001Age0.98 (0.96--0.999)0.0430.99 (0.97--1.00)0.0881.02 (0.98--1.05)0.3301.04 (0.99--1.08)0.111Sex (male)1.54 (0.92--2.57)0.0981.31 (0.80--2.14)0.2810.50 (0.23--1.10)0.0830.47 (0.19--1.16)0.101Atrial fibrillation0.94 (0.44--2.00)0.8620.68 (0.32--1.42)0.3000.93 (0.28--3.12)0.9061.29 (0.59--2.81)0.5261.33 (0.50--3.55)0.572Hyperlipidemia0.69 (0.30--1.60)0.3850.13 (0.03--0.59)0.008Smoking1.36 (0.81--2.27)0.2471.39 (0.84--2.31)0.199Prior anticoagulant treatment1.92 (0.60--6.09)0.2703.78 (0.71--20.1)0.119Congestive heart failure1.31 (0.31--5.51)0.714Baseline variables with a *p* value \<0.1 in univariate analysis were included in multivariate logistic regression models for each outcome. Favorable and good outcomes: TOAST classification, initial NIHSS, age, sex, atrial fibrillation and smoking; symptomatic ICH: TOAST classification, initial NIHSS, age, sex, atrial fibrillation and hyperlipidemia; any hemorrhage: TOAST classification, initial NIHSS, atrial fibrillation and prior anticoagulant treatment; mortality: initial NIHSS, age, sex, atrial fibrillation, hyperlipidemia, prior anticoagulant treatment and congestive heart failure

The ratio of any hemorrhage and sICH was highest in those with CE and lowest in those with SVD (Table [1](#Tab1){ref-type="table"}). The ratio of sICH was significantly higher in those with CE than in those with SVD (*p* = 0.005), whereas the ratio of any hemorrhage in those with SVD was significantly lower than in those with any other stroke subtype. More patients with CE received antiplatelet or anticoagulant treatment than those with LAA (*p* \< 0.001 and *p* = 0.004). However, after adjusting for confounding factors, sICH was not significantly different between the stroke subtypes, although the patients with SVD still had a significantly lower ratio of any hemorrhage compared to those with any other stroke subtype. Initial NIHSS was associated with sICH independently of the underlying factors (Table [2](#Tab2){ref-type="table"}). A higher NIHSS and absence of hyperlipidemia were significantly associated with a higher mortality rate (Table [2](#Tab2){ref-type="table"}).

Discussion {#Sec5}
==========

Our findings show that SVD after intravenous thrombolytic treatment was associated with a better outcome than LAA and a lower intracranial hemorrhage rate than any other stroke subtype, even after adjusting for confounding factors. The patients with CE had a higher rate of sICH than those with SVD, however the difference disappeared after adjusting for initial stroke severity. Initial stroke severity was an independent factor for favorable and good outcomes, sICH, and mortality in the patients treated with thrombolytic treatment.

These results support that the patients with SVD who were treated with tPA had better clinical outcomes, even after adjusting for baseline confounding factors. However, previous studies have reported no differences between stroke subtypes with or without adjusting for confounding factors (Fuentes et al. [@CR8]; Cocho et al. [@CR5]; Hsia et al. [@CR11]). Although the ECASS and NINDS trials showed the efficacy of intravenous tPA in all patients regardless of stroke subtype (The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group [@CR2]; Hacke et al. [@CR10]), a subsequent study proposed that the benefits for patients with SVD may be attributable to a younger age and milder stroke severity (Hsia et al. [@CR11]; Fluri et al. [@CR7]). Moreover, SVD is not thought to be susceptible to reperfusion treatment (Cocho et al. [@CR5]) due to the lack of existing lysible clots and penumbra (Hwang et al. [@CR13]). However, several studies have reported that patients with lacunar stroke may have better outcomes after thrombolysis (Lahoti et al. [@CR18]; Shobha et al. [@CR25]). In the current study and a study by Mustanoja et al. ([@CR20]), SVD was an independent factor for a good prognosis. In addition, some pathophysiology of lacunar infarcts has been attributed to atheroma or embolism rather than lipohyalinosis alone (Wardlaw et al. [@CR28]; Jeong et al. [@CR15]), and perfusion defects have been observed in lacunar infarcts on magnetic resonance perfusion scans (Poppe et al. [@CR23]; Huang et al. [@CR12]), supporting the micro-penumbra hypothesis. Thus, thrombolytic treatment may be beneficial for these patients.

Increasing evidence indicates that the natural course of patients with minor ischemic stroke is not as good as previously thought (Guerrero and Savitz [@CR9]). Early neurological deterioration (END) has been reported to occur in 20--30 % patients with SVD despite minor stroke symptoms (Hwang et al. [@CR13]; Audebert et al. [@CR3]), and this may lead to functional disability (lower Barthel Index score) (Audebert et al. [@CR3]). A recent study also demonstrated that END in patients with acute lacunar infarction is associated with the transformation of non-core hypoperfused areas into infarctions (Huang et al. [@CR12]), suggesting that a lysible clot may prevent END. In our study, 15 of 82 patients with SVD had minor stroke severity with a NIHSS ≤5. Our results indicate that patients with SVD, and usually those with minor stroke symptoms, had better outcomes and a lower intracranial hemorrhage rate. Therefore, intravenous tPA treatment may be beneficial for patients with SVD even if they only have minor symptoms.

SVD was associated with a low incidence of symptomatic ICH in the current study (1.6 %) and other studies (0 and 4.6 %) (Hsia et al. [@CR11]; Fluri et al. [@CR7]). In contrast, SVD was associated with a higher prevalence of microbleeds, ranging from 45.7 to 62.1 %, compared to the other stroke subtypes (Cordonnier et al. [@CR6]; Schonewille et al. [@CR24]; Naka et al. [@CR21]; Kato et al. [@CR16]). Since microbleeds are highly associated with lobar ICH from cerebral amyloid angiopathy, they are presumably associated with an increased risk of bleeding. However, the symptomatic ICH rate in the patients with SVD after thrombolysis was not higher than expected based on the high percentage of microbleeds. A possible reason for this is that microbleeds are markers of SVD representing underlying pathologies of hypertensive vasculopathy or amyloid angiopathy rather than real-time bleeding. Moreover, the microbleeds in SVD are more likely due to hypertensive vasculopathy, which is less associated with ICH (Inzitari et al. [@CR14]; Smith et al. [@CR26]). Therefore, further studies are needed to clarify whether microbleeds increase the rate of hemorrhage after thrombolysis.

Our results revealed that the patients with CE stroke had a higher rate of sICH than those with SVD, however the difference disappeared after adjusting for confounding factors. The higher rate of sICH may be due to the greater severity of stroke in the patients with CE stroke due to the large infarct areas. In addition, CE stroke is related to a larger core infarct and smaller penumbra (Kim et al. [@CR17]), and a larger core infarct has been reported to be associated with sICH, especially in patients with early reperfusion after thrombolytic therapy (Albers et al. [@CR1]). Therefore, the rate of sICH should be higher in patients with CE, especially in those with a larger infarct and early recanalization.

Although the fresh blood clots in CE stroke should be more sensitive to thrombolytic agents, we found no significant difference in favorable or good outcomes between the patients with CE and LAA strokes after adjusting for underlying confounding factors. A possible reason for this is that the greater disease severity in CE may mean that the blood clot in the occluded vessel is bigger and more difficult to dissolve. Another possible reason is that the penumbra to core infarct ratio is usually lower in CE than in LAA (Kim et al. [@CR17]), and that the effect of intravenous tPA treatment may be limited despite recanalization. Finally, CE was associated with a higher rate of sICH compared to LAA stroke (11.5 vs. 4.3 %, *p* = 0.035), and this may be related to the poorer outcomes.

A potential limitation to the current study is that we did not compare the outcomes of SVD directly between patients receiving thrombolysis and a placebo. However, a placebo-controlled study comparing intravenous tPA outcomes may be not ethically acceptable. Moreover, mRS was evaluated at discharge rather than at 3 months. Although the mRS at discharge has been reported to be highly correlated with the final functional outcome (Banks and Marotta [@CR4]), there may be some discrepancies concerning the actual recovery after stroke. In addition, this study is limited by the small number of cases, which also consists of heterogeneous data.

Conclusion {#Sec6}
==========

SVD after intravenous thrombolysis was associated with favorable outcomes and fewer hemorrhages even after adjusting for confounding factors. Initial stroke severity was an independent factor for a better outcome, sICH, any hemorrhage, and mortality rate regardless of the stroke subtype.
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